Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
FULC logo FULC
Upturn stock ratingUpturn stock rating
FULC logo

Fulcrum Therapeutics Inc (FULC)

Upturn stock ratingUpturn stock rating
$6.65
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: FULC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $11.07

1 Year Target Price $11.07

Analysts Price Target For last 52 week
$11.07 Target price
52w Low $2.31
Current$6.65
52w High $9.3

Analysis of Past Performance

Type Stock
Historic Profit 4.51%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 359.71M USD
Price to earnings Ratio -
1Y Target Price 11.07
Price to earnings Ratio -
1Y Target Price 11.07
Volume (30-day avg) 7
Beta 2.47
52 Weeks Range 2.31 - 9.30
Updated Date 08/28/2025
52 Weeks Range 2.31 - 9.30
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.18

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -19.77%
Return on Equity (TTM) -30%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 152087228
Price to Sales(TTM) 5.12
Enterprise Value 152087228
Price to Sales(TTM) 5.12
Enterprise Value to Revenue 117.4
Enterprise Value to EBITDA -3.09
Shares Outstanding 54091600
Shares Floating 14586338
Shares Outstanding 54091600
Shares Floating 14586338
Percent Insiders 1.82
Percent Institutions 101.55

ai summary icon Upturn AI SWOT

Fulcrum Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Fulcrum Therapeutics Inc. was founded in 2016. It is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with genetically defined rare diseases.

business area logo Core Business Areas

  • Therapeutic Development: Focused on developing therapies for genetically defined rare diseases, using FulcrumSeek platform to identify drug targets.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in drug development and biotechnology. The organizational structure is typical of a biotechnology company, with research, development, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • Losmapimod: A selective p38 alpha/beta MAP kinase inhibitor in clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Losmapimod is designed to reduce DUX4 expression. Competitors include Acceleron Pharma (acquired by Merck, focuses on other rare diseases but has muscular disease pipeline). Current market share for the treatment of FSHD is effectively zero for all companies as there is no approved treatment. The potential TAM will dictate future market shares.

Market Dynamics

industry overview logo Industry Overview

The industry is characterized by high growth potential driven by unmet medical needs in rare diseases. It's highly competitive with significant investment in R&D.

Positioning

Fulcrum Therapeutics is positioned as a pioneer in developing therapies for genetically defined rare diseases, leveraging its proprietary FulcrumSeek platform.

Total Addressable Market (TAM)

The TAM for rare disease therapies is substantial, estimated to be in the tens of billions of dollars annually. Fulcrum is positioned to capture a portion of this market through successful development and commercialization of its pipeline.

Upturn SWOT Analysis

Strengths

  • Proprietary FulcrumSeek platform
  • Strong focus on genetically defined rare diseases
  • Experienced management team
  • Losmapimod in clinical development

Weaknesses

  • Single late-stage asset, Losmapimod carries high risk
  • Limited financial resources compared to larger pharmaceutical companies
  • Reliance on clinical trial outcomes
  • No approved products generating revenue

Opportunities

  • Expanding the pipeline with new targets identified by FulcrumSeek
  • Potential for strategic partnerships and collaborations
  • Positive clinical trial results leading to regulatory approval
  • Expanding market reach to new geographies

Threats

  • Clinical trial failures
  • Competition from other companies developing therapies for rare diseases
  • Regulatory hurdles and changes in approval processes
  • Economic downturn affecting funding for biotechnology companies

Competitors and Market Share

competitor logo Key Competitors

  • DMD (DyhR)
  • VRTX (Vertex Pharmaceuticals)
  • MRK (Merck)

Competitive Landscape

Fulcrum faces competition from established pharmaceutical companies and other biotechnology firms developing therapies for rare diseases. Success hinges on the efficacy and safety of its products.

Growth Trajectory and Initiatives

Historical Growth: Growth is primarily driven by advancement of its pipeline and R&D activities.

Future Projections: Future growth depends on the success of Losmapimod and other pipeline programs. Analyst projections vary based on clinical trial results and regulatory approvals.

Recent Initiatives: Continued clinical development of Losmapimod, expanding pipeline with new targets from FulcrumSeek, and exploring strategic partnerships.

Summary

Fulcrum Therapeutics is a clinical-stage company with a promising platform and lead asset targeting rare diseases. Its future hinges on clinical trial success and regulatory approvals. Competition in the rare disease space is intense, and the company faces financial risks given its reliance on external funding. Strong pipeline development and successful commercialization are crucial for sustained growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports

Disclaimers:

This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Fulcrum Therapeutics Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2019-07-18
CEO, President & Director Mr. Alexander C. Sapir
Sector Healthcare
Industry Biotechnology
Full time employees 45
Full time employees 45

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.